NephrologyOnline.net

Nephrology Xagena

Search results for "Autosomal dominant polycystic kidney disease"

The FDA ( Food and Drug Administration ) has advised healthcare professionals of significant liver injury associated with the use of Samsca ( Tolvaptan ). In a double-blind, 3-year, placebo-controlled ...


Vasopressin V2-receptor antagonists may delay disease progression in autosomal dominant polycystic kidney disease ( ADPKD ). Trials with V2-receptor antagonists have been performed predominantly i ...


Autosomal dominant polycystic kidney disease ( ADPKD ) is a major cause of end-stage kidney failure, but is often identified early and therefore amenable to timely treatment. Interventions known to ...


The role of hyperuricemia in disease progression of autosomal dominant polycystic kidney disease ( ADPKD ) has not been defined well. Researchers have investigated the association of serum uric acid ...


In autosomal dominant polycystic kidney disease ( ADPKD ), progressive kidney cyst formation commonly leads to end-stage renal disease ( ESRD ). Because important manifestations of ADPKD may be evid ...


The two largest studies of mammalian target of rapamycin inhibitor treatment of autosomal dominant polycystic kidney disease ( ADPKD ) have demonstrated no clear benefit on the primary endpoint of tot ...


Hypertension is common in autosomal dominant polycystic kidney disease ( ADPKD ) and is associated with increased total kidney volume, activation of the renin–angiotensin–aldosterone system, and progr ...


Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease ( ADPKD ). One of the studies also showed that rig ...